JP7350019B2 - 筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法 - Google Patents

筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法 Download PDF

Info

Publication number
JP7350019B2
JP7350019B2 JP2020565903A JP2020565903A JP7350019B2 JP 7350019 B2 JP7350019 B2 JP 7350019B2 JP 2020565903 A JP2020565903 A JP 2020565903A JP 2020565903 A JP2020565903 A JP 2020565903A JP 7350019 B2 JP7350019 B2 JP 7350019B2
Authority
JP
Japan
Prior art keywords
als
peptide
certain embodiments
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020565903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524858A (ja
JPWO2019229757A5 (https=
JP2021524858A5 (https=
Inventor
エラン オヴァディア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunity Pharma Ltd
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of JP2021524858A publication Critical patent/JP2021524858A/ja
Publication of JPWO2019229757A5 publication Critical patent/JPWO2019229757A5/ja
Publication of JP2021524858A5 publication Critical patent/JP2021524858A5/ja
Application granted granted Critical
Publication of JP7350019B2 publication Critical patent/JP7350019B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2020565903A 2018-05-31 2019-05-30 筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法 Active JP7350019B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678316P 2018-05-31 2018-05-31
US62/678,316 2018-05-31
PCT/IL2019/050619 WO2019229757A1 (en) 2018-05-31 2019-05-30 Compositions and methods of using same for treating amyotrophic lateral sclerosis (als)

Publications (4)

Publication Number Publication Date
JP2021524858A JP2021524858A (ja) 2021-09-16
JPWO2019229757A5 JPWO2019229757A5 (https=) 2022-05-25
JP2021524858A5 JP2021524858A5 (https=) 2022-05-25
JP7350019B2 true JP7350019B2 (ja) 2023-09-25

Family

ID=68697171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565903A Active JP7350019B2 (ja) 2018-05-31 2019-05-30 筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法

Country Status (7)

Country Link
US (1) US20210100869A1 (https=)
EP (1) EP3785279A4 (https=)
JP (1) JP7350019B2 (https=)
AU (2) AU2019277920A1 (https=)
IL (1) IL279108B2 (https=)
MX (1) MX2020012532A (https=)
WO (1) WO2019229757A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528151A (ja) 2000-03-31 2003-09-24 スミスクライン ビーチャム パブリック リミテッド カンパニー 神経変性疾患等の疾患の治療または予防のためのｃｒｆ受容体アゴニストの使用
JP2008510796A (ja) 2004-08-23 2008-04-10 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
JP2010509345A (ja) 2006-11-10 2010-03-25 ジェナボン バイオファーマシューティカルズ エルエルシー Ｍｎｔｆペプチドおよびその類似体を用いて神経細胞障害を治療する方法
US20160033529A1 (en) 2011-05-23 2016-02-04 Universitätsklinikum Hamburg-Eppendorf Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2016040877A1 (en) 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
SK151599A3 (en) 1997-05-14 2000-09-12 Rhone Poulenc Rorer Pharma Peptide parathyroid hormone analogs
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
AU2005298383A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
CA2689476C (en) * 2007-06-07 2014-08-05 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
CA3193811A1 (en) * 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528151A (ja) 2000-03-31 2003-09-24 スミスクライン ビーチャム パブリック リミテッド カンパニー 神経変性疾患等の疾患の治療または予防のためのｃｒｆ受容体アゴニストの使用
JP2008510796A (ja) 2004-08-23 2008-04-10 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
JP2010509345A (ja) 2006-11-10 2010-03-25 ジェナボン バイオファーマシューティカルズ エルエルシー Ｍｎｔｆペプチドおよびその類似体を用いて神経細胞障害を治療する方法
US20160033529A1 (en) 2011-05-23 2016-02-04 Universitätsklinikum Hamburg-Eppendorf Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2016040877A1 (en) 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immunology, 2017, Vol.151, pp.474-480

Also Published As

Publication number Publication date
JP2021524858A (ja) 2021-09-16
US20210100869A1 (en) 2021-04-08
AU2025201060A1 (en) 2025-03-20
IL279108B1 (en) 2024-06-01
CA3099846A1 (en) 2019-12-05
EP3785279A4 (en) 2022-07-27
IL279108B2 (en) 2024-10-01
WO2019229757A1 (en) 2019-12-05
EP3785279A1 (en) 2021-03-03
MX2020012532A (es) 2021-04-28
AU2019277920A1 (en) 2021-01-07
IL279108A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
CN114929209A (zh) 肌萎缩侧索硬化的治疗
JP2021119189A (ja) ジストニアを治療するためのプリドピジンの使用
ES2912306T3 (es) Tetratiomolibdato de bis-colina para el tratamiento de enfermedad de Wilson
JP2007510736A (ja) 多発性硬化症に付随する症状を治療するためのデルタ−９−ｔｈｃ組成物及び方法
US20100061935A1 (en) Methods of using sustained release aminopyridine compositions
WO2007046347A1 (ja) 筋萎縮性側索硬化症患者の運動神経保護用医薬
CN102143686A (zh) 用4-氨基吡啶持续治疗脱髓鞘病患者
JP7350019B2 (ja) 筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法
RU2851806C1 (ru) Композиции и способы их применения для лечения амиотрофического латерального склероза (als)
EP4228646A1 (en) Treatment of cognitive impairment with a cns-penetrant sgc stimulator
RU2804764C2 (ru) Композиции и способы их применения для лечения амиотрофического латерального склероза (als)
CA3099846C (en) Compositions and methods of using same for treating amyotrophic lateral sclerosis (als)
CN119654149A (zh) 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法
JP2002522507A (ja) 疾患状態の処置
CA2155540A1 (en) Methods for treating amyotrophic lateral sclerosis with cntf
Hassanian-Moghaddam et al. The report of suicide by ingestion of lidocaine topical spray
JP2019517516A (ja) Ｓｍａの新規な処置
Linfield et al. Impact of Apitegromab on Motor Function in Spinal Muscular Atrophy
WO2024054412A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
KR20260005781A (ko) 만성 염증성 탈수초 다발신경병증에 대한 펩타이드의 투여요법
WO2026011229A1 (en) Novel therapy
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
CN117897138A (zh) 呼吸系统病症的治疗
WO2021180087A1 (zh) 淫羊藿苷元的医药用途

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230912

R150 Certificate of patent or registration of utility model

Ref document number: 7350019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150